Jayson Bedford
Stock Analyst at Raymond James
(3.99)
# 623
Out of 4,759 analysts
302
Total ratings
57.89%
Success rate
8.48%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $126 → $119 | $100.52 | +18.38% | 7 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $106.11 | +14.98% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $595.55 | +15.52% | 8 | Jan 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $170 → $165 | $156.15 | +5.67% | 21 | Jan 23, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $105 → $110 | $108.14 | +1.72% | 26 | Dec 31, 2024 | |
| MASI Masimo | Maintains: Outperform | $170 → $194 | $181.31 | +7.00% | 6 | Dec 27, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $89.07 | +11.15% | 30 | Oct 25, 2024 | |
| PODD Insulet | Maintains: Outperform | $213 → $260 | $280.56 | -7.33% | 25 | Oct 14, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $130.61 | -1.23% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $160.16 | +18.63% | 19 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $224.80 | +20.11% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $18.13 | -28.30% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $10.34 | -3.29% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $167.43 | +61.86% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.30 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.47 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $76.19 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.82 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $92.81 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $1.24 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $63.24 | +35.99% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.13 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $24.18 | - | 3 | Jan 2, 2018 |
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $126 → $119
Current: $100.52
Upside: +18.38%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $106.11
Upside: +14.98%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $595.55
Upside: +15.52%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $170 → $165
Current: $156.15
Upside: +5.67%
Merit Medical Systems
Dec 31, 2024
Maintains: Outperform
Price Target: $105 → $110
Current: $108.14
Upside: +1.72%
Masimo
Dec 27, 2024
Maintains: Outperform
Price Target: $170 → $194
Current: $181.31
Upside: +7.00%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $89.07
Upside: +11.15%
Insulet
Oct 14, 2024
Maintains: Outperform
Price Target: $213 → $260
Current: $280.56
Upside: -7.33%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $130.61
Upside: -1.23%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $160.16
Upside: +18.63%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $224.80
Upside: +20.11%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $18.13
Upside: -28.30%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $10.34
Upside: -3.29%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $167.43
Upside: +61.86%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.30
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.47
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $76.19
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.82
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $92.81
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $1.24
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $63.24
Upside: +35.99%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.13
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $24.18
Upside: -